All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

    KCE Reports 127 (2010)

    https://kce.fgov.be/en/publication/report/cost-effectiveness-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium-part-
  2. Children in a playground

    Cost-effectiveness analysis of HPV vaccination of boys in Belgium

    KCE Reports 308 (2019) The vaccine for the human papilloma virus (HPV) which causes cervical cancer was introduced about ten years ago in Belgium, but only girls benefit from it. However, it is now established that this same virus is also involved in other cancers, including throat cancer. The recommendations have thus been reviewed and here, as in most western countries, it is now recommended to vaccinate boys too.

    https://kce.fgov.be/en/cost-effectiveness-analysis-of-hpv-vaccination-of-boys-in-belgium

  3. Barriers and opportunities for the uptake of biosimilar medicines in Belgium

    KCE Reports 199 (2013)

    https://kce.fgov.be/en/publication/report/barriers-and-opportunities-for-the-uptake-of-biosimilar-medicines-in-belgium

  4. Antiviral agents in seasonal and pandemic influenza. Literature study and development of practice guidelines

    KCE Reports 49 (2006)

    https://kce.fgov.be/en/publication/report/antiviral-agents-in-seasonal-and-pandemic-influenza-literature-study-and-developm

  5. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

    KCE Reports 231 (2014)

    https://kce.fgov.be/en/publication/report/a-quadrivalent-vaccine-against-serogroup-b-meningococcal-disease-a-cost-effective

  6. [Vaccine safety surveillance in Belgium : place and limits of a background rate approach]

    KCE Reports 188 (2012)

    https://kce.fgov.be/en/publication/report/vaccine-safety-surveillance-in-belgium-place-and-limits-of-a-background-rate-appr

  7. [Statins in Belgium: utilization trends and impact of reimbursement policies]

    KCE Reports 141 (2010)

    https://kce.fgov.be/en/publication/report/statins-in-belgium-utilization-trends-and-impact-of-reimbursement-policies

  8. [Financing of hospital drugs: a descriptive study of several European countries and Canada]

    KCE Reports 8 (2005)

    https://kce.fgov.be/en/publication/report/financing-of-hospital-drugs-a-descriptive-study-of-several-european-countries-and

  9. [Effectiveness and cost-effectiveness of treatments for smoking cessation]

    KCE Reports 1 (2004) 22 juillet 2004 (1st print), août 2005 (2nd print)

    https://kce.fgov.be/en/publication/report/effectiveness-and-cost-effectiveness-of-treatments-for-smoking-cessation

  10. [Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

    KCE Reports 157 (2011)

    https://kce.fgov.be/en/publication/report/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium

  11. [Antibiotics use in hospitals for acute pyelonephritis]

    KCE Reports 3 (2004)

    https://kce.fgov.be/en/publication/report/antibiotics-use-in-hospitals-for-acute-pyelonephritis

Pages